Table 2. Correlation between VEGF-C and VEGFR-3 mRNA expression and clinicopathological factor.

Clinicopathological factors	No. of patients	VEGF-C	P-value	VEGFR-3	P-value
Age
70>	40	50.8±58.3	0.15	70.8±128.2	0.07
70⩽	34	33.6±41.5		31.3±38.0
Gender
Male	54	41.2±49.1	0.64	35.4±53.4	0.1
Female	20	47.5±59.3		99.3±163.3
T
1	28	51.7±62.3	0.17	85.9±148.9	0.09
2	32	32.5±44.8		34.4±43.7
N
(−)	48	50.6±57.0	0.08	71.7±118.2	0.003
(+)	26	28.7±37.0		17.5±21.6
Stage
I, II	51	48.3±57.5	0.11	66.1±116.1	0.08
III, IV	23	31.0±33.6		22.9±25.0
Histological type
Adenocarcinoma	39	56.6±60.4	0.006	81.3±126.8	0.003
Squamous cell ca	32	24.5±33.1		15.3±24.4
Differentiation
Adenocarcinoma
Well	16	53.0±55.3	0.76	120.2±177.3	0.11
Mod or Poor	23	59.1±64.8		35.9±54.1
Squamous cell ca
Well	6	26.4±38.7	0.88	18.3±19.5	0.75
Mod or Poor	26	24.0±32.6		14.7±25.7

VEGF-C: vascular endothelial growth factor-C;

VEGFR-3: vascular endothelial growth factor receptor-3.